Blenrep (Belantamab Mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate used for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously taken at least four therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Dosage: The recommended dosage of Blenrep is 2.5 mg/kg of actual body weight, should be administered as an intravenous infusion over approximately 30 minutes once every three weeks until the disease is progressive or unacceptable toxicity occurs.
Side Effects: The most commonly reported belantamab mafodotin side effects (incidence ≥20%) include:
- Blurred vision
- Decreased visual acuity
- Infusion-related reactions
- Keratopathy (corneal epithelium change on eye exam)
Warnings and Precautions:
- Perform an ophthalmic exam prior to initiation of blenrep 100 mg and during treatment.
- Patients with blenrep are advised to use preservative-free lubricant eye drops and avoid contact lenses unless directed by an ophthalmologist.
- Perform complete blood cell counts at baseline and during treatment with blenrep drug as clinically indicated.
- Monitor patients with Belantamab Mafodotin-blmf for infusion-related reactions.
- Based on its mechanism of action, blenrep uses can be responsible for causing fetal harm if administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F) and it targets actively dividing cells.
- Because of the risk for serious adverse reactions in the breastfed child, advise women not to breastfeed while on blenrep dosing and for 3 months after the last dose.